Results 231 to 240 of about 117,898 (292)

Hematological events and thyroid status in Imatinib treated CML Iraqi

, 2018
Khaleed J. Khaleel
openalex   +2 more sources

Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF-MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib. [PDF]

J Clin Med
Kawczak P, Bączek T.
europepmc   +1 more source

BCR::ABL1-positive chronic myeloid leukaemia in a scenario of a remote diagnosis of JAK2-V617F-mutated polycythemia vera: a single patient experience with imatinib and ruxolitinib combination therapy. [PDF]

Ann Hematol
Bartolucci P, Gigli F, Tabanelli V, Valeriano A, Gregato G, Poletti C, Bertolini F, Derenzini E.   +7 more
europepmc   +1 more source

Drug-drug interactions in targeted cancer therapies: a focus on tyrosine kinase inhibitors. [PDF]

Expert Rev Clin Pharmacol
Stromatt JC, Chowdhury AT, Huang KM, Hu S, Sparreboom A, Baker SD, Eisenmann ED.   +6 more
europepmc   +1 more source

Resistance to imatinib in a <i>ETV6::PDGFRB</i> rearranged myeloid/lymphoid neoplasm with high-risk mutations: a case report. [PDF]

Front Oncol
Cavelier L, Saft L, Sander B, Deneberg S.   +3 more
europepmc   +1 more source

Response Assessment of Generic Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Prospective Study from a Tertiary Care Centre in North Eastern India. [PDF]

Cureus
Choudhuri A, Bhattacharyya J, Das S, Das D, Dhameja N.   +4 more
europepmc   +1 more source

In-depth analysis for TKI-driven real-world management of 201 CML patients using TFR. [PDF]

Front Pharmacol
Micu ML, Cira SF, Zdrenghea M, Bojan A, Parvu A, Torok-Vistai T, Vasilache A, Urian L, Anamaria B, Jimbu LI, Santa ME, Lighezan D, Tigu AB, Ivancuta A, Trifa A, Selicean EC, Dima D, Ioana Codruța R, Tomuleasa C.   +18 more
europepmc   +1 more source

Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis. [PDF]

Blood Vessel Thromb Hemost
Travers R, Stepanian A, Redford S, Martin G, Svedberg NL, Xu K, Merrill-Skoloff G, Chen C, Flaumenhaft R, Jaffe IZ.   +9 more
europepmc   +1 more source

Study Protocol from KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial

Heikki Joensuu, Eva Wardelmann, Mikael Eriksson, Annette Reichardt, Kirsten Sundby Hall, Jochen Schütte, Silke Cameron, Peter Hohenberger, Harri Sihto, Philipp J. Jost, Lars H. Lindner, Sebastian Bauer, Bengt Nilsson, Raija Kallio, Tommi Pesonen, Peter Reichardt   +15 more
openalex   +1 more source

The Imatinib-miR-335-5p-ARHGAP18 Axis Attenuates PDGF-Driven Pathological Responses in Pulmonary Artery Smooth Muscle Cells. [PDF]

Int J Mol Sci
Lee Y, Kang H.
europepmc   +1 more source